Claims for Patent: 9,976,171

Summary for Patent: 9,976,171

Title:	Method for dissolution testing of solid compositions containing digestive enzymes
Abstract:	The invention is directed to a process for measuring the amount of digestive enzymes released from a solid composition in a dissolution medium by fluorescence spectroscopy. The invention is also directed to a combined method for measuring both the dissolution and gastroresistance of a solid compositions comprising pancrelipase.
Inventor(s):	Latino; Massimo (Cinisello Balsamo, IT), Ghidorsi; Luigi (Milan, IT), Ortenzi; Giovanni (Monza, IT)
Assignee:	ALLERGAN PHARMACEUTICALS INTERNATIONAL LIMITED (IE)
Application Number:	14/237,180
Patent Claims:	1. A process for measuring an amount of digestive enzymes released from a solid pancrelipase composition in a dissolution medium using fluorescence spectroscopy for measuring the amount of digestive enzymes released from the composition in the dissolution medium, the process comprising the steps of: (a) allowing the solid pancrelipase composition to release the digestive enzymes in the dissolution medium, and (b) reading the fluorescence to measure the amount of digestive enzymes in the medium, wherein the dissolution medium includes at least two media that are applied sequentially, wherein the step (a) further comprises adding the solid pancrelipase composition in a first dissolution medium to form a suspension, transferring the suspension in a second dissolution medium, and allowing the release of the digestive enzymes, and the step (b) further comprises sampling aliquots of dissolution medium, reading fluorescence at 346 nm, and calculating the amount of digestive enzymes released. 2. The process of claim 1, wherein the solid pancrelipase composition is an enteric coated pancrelipase composition. 3. The process of claim 1, wherein the dissolution medium includes at least two media selected from the group consisting of water, HC1 solution, simulated gastric fluid, buffer solution, simulated intestinal fluid, aqueous and buffer solution containing at least one surfactant. 4. The process of claim 1, wherein the first dissolution medium is an aqueous medium having pH between about 1 and about 4.5 and the second dissolution medium is aqueous buffer solution having pH above about 5. 5. The process of claim 1, wherein the first dissolution medium is an aqueous medium having pH between about 1 and about 2. 6. The process of claim 1, wherein the second dissolution medium is aqueous buffer solution having pH between about 5.5 and about 6.8. 7. The process of claim 1, wherein the first dissolution medium is an aqueous medium having pH of about 1.2 and the second dissolution medium is aqueous buffer solution having pH of about 6. 8. The process of claim 1, wherein the solid pancrelipase composition has a total of about 750, about 3,000, about 4,200, about 5,000, about 6,000, about 10,000, about 10,500, about 15,000, about 16,800, about 20,000, about 21,000, about 24,000, or about 25,000, or about 40,000 USP lipase units or multiple thereof; or about 5,000, or about 10,000, or about 15,000 or about 20,000 or about 30,000, or about 40,000 PhEur lipase units or multiple thereof. 9. The process of claim 1 combined with a gastroresistance test, wherein a residual lipase activity of the composition in aqueous medium having pH between about 1 and about 4.5 is measured by an enzymatic lipase assay method. 10. The process of claim 9 combined with a gastroresistance test, wherein a residual lipase activity of the composition in aqueous medium having pH between about 1 and about 2 is measured by the enzymatic lipase assay method. 11. The process of claim 9 combined with a gastroresistance test, wherein a residual lipase activity of the composition in aqueous medium having pH of about 1.2 is measured by the enzymatic lipase assay method. 12. The process of claim 9 wherein the measuring of the amount of digestive enzymes released from the solid composition in dissolution medium by fluorescence spectroscopy is carried out either before or after the gastroresistance test. 13. The process of claim 12, wherein the measuring of the amount of digestive enzymes released from the solid composition in dissolution medium by fluorescence spectroscopy is carried in dissolution medium that consists of at least two media that are used sequentially. 14. The process of claim 13, wherein the first dissolution medium is an aqueous medium having acid pH between about 1 and about 4.5. 15. The process of claim 13, wherein the first dissolution medium is an aqueous medium having pH between about 1 and about 2. 16. The process of claim 13, wherein the second dissolution medium is aqueous buffer solution having pH above about 5. 17. The process of claim 13, wherein the second dissolution medium is aqueous solution having pH between about 5.5 and about 6.8. 18. The process of claim 13, wherein the first dissolution medium is an aqueous medium having pH of about 1.2 and the second dissolution medium is aqueous buffer solution having pH of about 6. 19. The process of claim 9 wherein the pancrelipase compositions have a total of about 750, about 3,000, about 4,200, about 5,000, about 6,000, about 10,000, about 10,500, about 15,000, about 16,800, about 20,000, about 21,000, about 24,000, about 25,000, or about 40,000 USP lipase units or multiple thereof; or about 5,000, or about 10,000, or about 15,000 or about 20,000 or about 30,000, or about 40,000 PhEur lipase units or multiple thereof. 20. The process of claim 12, wherein the measuring of the amount of digestive enzymes released from the solid composition in dissolution medium by gastroresistance test is carried in aqueous medium having acid pH between about 1 and about 4.5.

Details for Patent 9,976,171

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Organon Usa Inc., A Subsidiary Of Merck & Co., Inc.	COTAZYM	pancrelipase	Capsule, Delayed Release	020580	12/09/1996		2040-03-30
Abbvie Inc.	CREON	pancrelipase	Capsule, Delayed Release	020725	04/30/2009		2040-03-30
Abbvie Inc.	CREON	pancrelipase	Capsule, Delayed Release	020725	06/10/2011		2040-03-30
Abbvie Inc.	CREON	pancrelipase	Capsule, Delayed Release	020725	03/14/2013		2040-03-30
Digestive Care, Inc.	PERTZYE	pancrelipase	Capsule, Delayed Release	022175	05/17/2012		2040-03-30